Lifevantage: Q2 Earnings Insights

Shares of Lifevantage LFVN moved higher in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 19.35% over the past year to $0.25, which beat the estimate of $0.22.

Revenue of $59,007,000 decreased by 3.65% from the same period last year, which missed the estimate of $64,070,000.

Outlook

Lifevantage hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Feb 02, 2021

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=142898

Technicals

Company's 52-week high was at $17.09

52-week low: $7.75

Price action over last quarter: down 13.59%

Company Description

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system, as well as Canine Health, a companion pet supplement formulated to combat oxidative stress in dogs. Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.